OmniClouds Standardizes on Versa Networks to Deliver Secure SD-WAN Across the Globe
OmniClouds, the leading innovator in the cloud service provider (CSP) space and migrator for the EMEA region, today announced that it has adopted the Versa Secure SD-WAN solution to offer and expand services across the globe, using OmniClouds’ comprehensive SDN-dedicated network offering a unique experience of true SLA-based cloud services.
OmniClouds platform connects its enterprise customers’ branches and remote users to multiple public and private clouds, lowering the expense and complications of cloud adoption Globally. It is offering Versa Networks, the leader in Secure SD-WAN providing software-defined networking over any type of connectivity for simplified management and dynamic support for cloud adoption and migration.
OmniClouds will not only provide full hybrid cloud connectivity but will also use Versa Networks as an overlay to existing connectivity technologies, such as IP-MPLS, microwave, satellite, LTE or public internet, to automate operations and enhance connectivity over large geographic regions. This will give its enterprise, government and SME customers a central management view of the entire network, enabling them to easily control security, user permissions and parameters, such as latency and quality of service.
OmniClouds will use Versa Cloud Gateways at each of the regions’ and counties’ main cloud service providers, which connect with Secure SD-WAN CPE running Versa Operating System (VOS™) at the enterprises’ data centers, headquarters and branch operations. This dramatically reduces customer operating costs, smooths their adoption of cloud services, and enables widespread connectivity across distant locations.
Amr A Eid, Group Chief Executive Officer and Board Member, OmniClouds, said: “OmniClouds is excited and proud of the strategic partnership with Versa Networks, the best in class for SD-WAN Technologies. We are a partner led global organization, addressing our SME, Public Sector and SOHO customers through our regional, local, white label ISPs across the globe. In doing so we look for strong partnerships for our network technology and visionary and trustworthy leadership, and Versa Networks is exceptional in all these aspects. We are confident that we are setting the standard for both cloud connectivity and smart applications management.”
“OmniClouds is a leader in optimizing, migrating, and supporting organizations’ migration from traditional internet connectivity models to modern, cloud-based network infrastructures,” said Kelly Ahuja, CEO of Versa Networks. “Secure SD-WAN is the pervasive method for businesses and organizations to securely, reliably, and seamlessly connect their offices, teleworkers, employees, staff, and partners globally to private data centers, cloud services, and SaaS. Versa is excited to be working with OmniClouds to deliver the best-of-breed solution for the growing Middle East and Africa regions.”
Versa Networks, VOS, and Versa Titan are or may be registered trademarks of Versa Networks, Inc. All other marks and names mentioned herein may be trademarks of their respective companies.
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200914005470/en/
Contact information
OmniClouds
Mr. Amr Eid
The Group CEO & Board member
media@omniclouds.com
Versa Networks
media@versa-networks.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Brenus Pharma Reports Favorable Tolerability and Clinical Signals in Early Preliminary Results of First-In-Human Study for STC-1010 in Unresectable Metastatic Stage Colorectal Cancer (MSS CRC) Patients6.1.2026 22:00:00 EET | Press release
Brenus Pharma, a clinical stage biotechnology company unlocking the immune system in vivo to fight solid tumors, announced the successful completion of the first dose levels in its ongoing first-in-human study. The multi-center, open-label trial (NCT06934538) is a phase Ia/Ib study designed to evaluate safety, tolerability and preliminary clinical activity of STC-10101 in a first line setting. It will include in vivo analysis of immune and tumor dynamics during dose escalation of treatment and cohort extension to patients with unresectable locally advanced (stage IIIC, T4b) or unresectable metastatic (stage IV) MSS2 colorectal cancer (CRC). Early findings indicate that the first dose levels have been successfully completed with good overall tolerance and no-dose-limiting toxicities observed to date. “We are pleased to report that the safety profile observed to date is good and consistent with our expectations with no DLT,” said Paul Bravetti, CEO of Brenus Pharma. “Moreover, preliminar
SPIE, the International Society for Optics and Photonics, Announces Its 2026 Fellows6.1.2026 21:35:00 EET | Press release
SPIE, the international society for optics and photonics, welcomes 40 Members as new Fellows of the Society in the 2026 cohort. They join their Fellow Member colleagues in being honored for their excellent technical achievements, as well as for their substantial service to the optics and photonics community and to SPIE. Fellows are Members of the Society who have made significant scientific and technical contributions in the multidisciplinary fields of optics, photonics, and imaging. Since the Society's inception in 1955, more than 1,800 SPIE Members have become Fellows. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260106630672/en/ SPIE, the international society for optics and photonics, announces its 2026 Fellows This year’s inductees are high-profile leaders in academia, industry, and government, many of whom are particularly prominent in their support of the optics and photonics community and mentorship of others. “It’
Chemelex Adds Electric Heat Trace Group Ltd.’s SmartTrace Monitoring Platform to its Heat Tracing Portfolio6.1.2026 21:00:00 EET | Press release
Chemelex, a global leader in electric thermal and sensing solutions, today announced the successful completion of its acquisition of substantially all the assets and ongoing operations of Electric Heat Trace Group Ltd. (EHT Group), headquartered in Ontario, Canada. This strategic move marks an exciting start to the new year and reinforces Chemelex’s commitment to delivering smarter, data-driven solutions for industrial heat trace systems. EHT Group is a recognized innovator in heat trace management, offering advanced software, integrated controller solutions, wireless communication modules, and comprehensive field services. Its flagship platform, SmartTrace, is a robust solution available in both cloud-based and on-premises deployments that enables predictive maintenance, minimizes downtime, and provides secure remote monitoring—helping customers achieve greater reliability and operational efficiency. This endeavor will help Chemelex support greater operational efficiencies for our cus
ZIIHERA Plus TEVIMBRA and Chemotherapy: A Potential New Standard for First-Line HER2+ Advanced GEA6.1.2026 20:30:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced full results from the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), a HER2-targeted bispecific antibody, in combination with chemotherapy, with and without PD-1 inhibitor TEVIMBRA® (tislelizumab), as a first-line treatment for HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). These data, including the first interim overall survival (OS) analysis, will be presented as a Late-Breaking Abstract Oral Presentation (#LBA285) at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) on January 8, 2026, from 8:57- 9:07 a.m. PST. HERIZON-GEA-01 met the dual primary endpoint of progression-free survival (PFS), demonstrating statistically significant and clinically meaningful improvements in both experimental arms compared to the control arm. The addition of TEVIMBRA to ZIIHERA and chemotherapy also sho
Siemens and NVIDIA Expand Partnership to Build the Industrial AI Operating System6.1.2026 19:07:00 EET | Press release
CES 2026 - Siemens and NVIDIA today announced a significant expansion of their strategic partnership to bring artificial intelligence into the real world. Together, the companies aim to develop industrial and physical AI solutions that will bring AI-driven innovation to every industry and industrial workflow, as well as accelerate each others’ operations. To support development, NVIDIA will provide AI infrastructure, simulation libraries, models, frameworks and blueprints, while Siemens will commit hundreds of industrial AI experts and leading hardware and software. “Together, we are building the Industrial AI operating system – redefining how the physical world is designed, built, and run - to scale AI and create real-world impact,” said Roland Busch, President and CEO of Siemens AG. “By combining NVIDIA’s leadership in accelerated computing and AI platforms with Siemens’ leading hardware, software, industrial AI and data, we’re empowering customers to develop products faster with the
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom